Human schistosomiasis

被引:214
作者
Gryseels, Bruno [1 ]
Polman, Katja [1 ]
Clerinx, Jan [1 ]
Kestens, Luc [1 ]
机构
[1] Inst Trop Med, B-2000 Antwerp, Belgium
关键词
D O I
10.1016/S0140-6736(06)69440-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Schistosomiasis or bilharzia is a tropical disease caused by worms of the genus Schistosoma. The transmission cycle requires contamination of surface water by excreta, specific freshwater snails as intermediate hosts, and human water contact. The main disease-causing species are S haematobium, S mansoni, and S japonicum. According to WHO, 200 million people are infected worldwide, leading to the loss of 1.53 million disability-adjusted life years, although these figures need revision. Schistosomiasis is characterised by focal epidemiology and overdispersed population distribution, with higher infection rates in children than in adults. Complex immune mechanisms lead to the slow acquisition of immune resistance, though innate factors also play a part. Acute schistosomiasis, a feverish syndrome, is mostly seen in travellers after primary infection. Chronic schistosomal disease affects mainly individuals with long-standing infections in poor rural areas. Immunopathological reactions against schistosome eggs trapped in the tissues lead to inflammatory and obstructive disease in the urinary system (S haematobium) or intestinal disease, hepatosplenic inflammation, and liver fibrosis (S mansoni, S japonicum). The diagnostic standard is microscopic demonstration of eggs in the excreta. Praziquantel is the drug treatment of choice. Vaccines are not yet available. Great advances have been made in the control of the disease through population-based chemotherapy but these required political commitment and strong health systems.
引用
收藏
页码:1106 / 1118
页数:13
相关论文
共 155 条
  • [1] Immunopathogenic mechanisms in schistosomiasis: what can be learnt from human studies?
    Abath, FGC
    Morais, CNL
    Montenegro, CEL
    Wynn, TA
    Montenegro, SML
    [J]. TRENDS IN PARASITOLOGY, 2006, 22 (02) : 85 - 91
  • [2] ABDELWAHAB MF, 1993, AM J GASTROENTEROL, V88, P560
  • [3] ALI MI, 1989, TROP MED PARASITOL, V40, P195
  • [4] APPLETON CC, 1984, S AFR MED J, V65, P467
  • [5] Efficacy of myrrh in the treatment of human Schistosomiasis mansoni
    Barakat, R
    Elmorshedy, H
    Fenwick, A
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2005, 73 (02) : 365 - 367
  • [6] The changing face of schistosomal glomerulopathy
    Barsoum, R
    Harrington, JT
    Mathew, CM
    El Nahas, AM
    Abboud, O
    Cannata-Andia, J
    El Sherif, A
    Abou Zeid, MH
    Malik, GH
    Matheson, P
    Ben Hamida, M
    El Hammady, MS
    Mohamed, K
    Francis, M
    Hassan, AA
    [J]. KIDNEY INTERNATIONAL, 2004, 66 (06) : 2472 - 2484
  • [7] Schistosomiasis and the risk of bladder cancer in Alexandria, Egypt
    Bedwani, R
    Renganathan, E
    El Kwhsky, F
    Braga, C
    Abu Seif, HH
    Abul Azm, T
    Zaki, A
    Franceschi, S
    Boffetta, P
    La Vecchia, C
    [J]. BRITISH JOURNAL OF CANCER, 1998, 77 (07) : 1186 - 1189
  • [8] Schistosomiasis vaccines: Research to development
    Bergquist, NR
    Colley, DG
    [J]. PARASITOLOGY TODAY, 1998, 14 (03): : 99 - 104
  • [9] Market reform: a challenge to public health - the case of schistosomiasis control in China
    Bian, Y
    Sun, Q
    Zhao, ZY
    Blas, E
    [J]. INTERNATIONAL JOURNAL OF HEALTH PLANNING AND MANAGEMENT, 2004, 19 : S79 - S94
  • [10] BLAS B L, 1986, Southeast Asian Journal of Tropical Medicine and Public Health, V17, P67